For immunotherapies, many candidate biomarkers such as IFN-γ and TGF-β are under investigation.[11] From the ASCO 2015 Annual Meeting, treatments targeting PD-1/PD-L1 pathway for NSCLC patients were widely reported. This evidence concerns the gene CD274 and non-small cell lung carcinoma.